Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Rapid relief of radiotherapy-related neuropathic pain (RRNP) in head and neck cancer (HNC) survivors is challenging when relying solely on pharmacologic treatments, especially in the early stages of medication. Whether transcutaneous auricular vagus nerve stimulation (taVNS) can effectively and rapidly control the RRNP in HNC survivors remains uncertain.
Methods: The RELAX trial was a randomised, parallel, sham-controlled trial conducted at four centres in China. We randomly assigned (1:1) HNC survivors with moderate-to-severe RRNP (as defined by Numeric Rating Scale [NRS] score of ≥4) to receive taVNS or sham stimulation (concha of the left ear) for 30 min twice daily over 7 days. Participants, outcome assessors, and statisticians were blinded to assignment and intervention. All patients also received a basal dose of pregabalin (75 mg twice daily). The primary outcome was pain intensity reduction, as measured by the change of NRS scores from baseline to day 7. This trial is registered at ClinicalTrials.gov, NCT05543239.
Findings: Between September 16, 2022, and December 1, 2023, 116 eligible patients (mean age, 50.8 [standard deviation (SD), 8.8] years; 40 [34.5%] were women) were randomly assigned into groups. All patients completed NRS score at baseline and day 7, and 112 (96.6%) completed 80% or more of the intervention course. The pain intensity at baseline was 5.79 (SD, 1.59) in the taVNS group and 5.66 (SD, 1.54) in the control group. At day 7, pain intensity decreased by 2.43 (SD, 2.19) in the taVNS group and 1.12 (SD, 1.64) in the Control group; between-group difference, 1.31 points (95% confidence interval [CI], 0.60-2.02; P = 0.00042). The most common adverse event (AE) related to taVNS was mild, transient local skin irritations at the electrode site (8.6% versus 1.7%, P = 0.21), and no serious AE were associated with the device.
Interpretation: In this trial, taVNS for 7 days at the initial stage of pregabalin treatment resulted in significantly better pain relief in HNC survivors with moderate-to-severe RRNP with no serious AE. Further prospective investigations to observe the longer term effects of taVNS on RRNP are warranted.
Funding: This study was supported by Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Department of Science and Technology of Guangdong Province and Guangzhou Science and Technology Bureau.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280346 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2025.103345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypoglossal Neuropathy in the Pathogenesis of Fibrosis-Related Late-Radiation Associated Dysphagia: A Correlative Analysis Utilizing Electromyography to Explore the Frequency of Clinical and Subclinical Neuropathy in a Pilot Dysphagia Trial.
Head Neck
September 2025
Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Background: Late radiation-associated dysphagia (late-RAD) commonly presents in patients with signs of hypoglossal neuropathy, with hallmark clinical features including lingual atrophy, deviation, and fasciculation. Gold-standard electromyography (EMG) has not been used to explore the frequency of hypoglossal neuropathy in patients with late-RAD.
Methods: Exploratory post hoc secondary analysis of MANTLE trial (NCT03612531) was completed.
Clinical and social determinants of survivorship clinic attendance in head and neck cancer.
J Cancer Surviv
September 2025
Department of Otolaryngology - Head and Neck Surgery, University of Pittsburgh Medical Center, 203 Lothrop St # 500, Pittsburgh, PA, 15213, USA.
Purpose: Despite its importance, little is known about the patterns and predictors of Survivorship Clinic attendance in head and neck cancer (HNC). We sought to determine the cumulative incidence of Survivorship Clinic attendance stratified by demographic, clinical, and socioeconomic factors, and to identify factors independently associated with attendance.
Methods: Our analysis population consisted of 2,252 patients diagnosed with primary HNC and seen at our institution's HNC Survivorship Clinic after completing treatment from 2016-2021.
Objective: This study aims to characterize the relationship of esophageal dysmotility on modified barium swallow (MBS) and esophagram studies with high-resolution manometry (HRM), the gold standard of esophageal dysmotility diagnosis, in head and neck cancer (HNC) survivors with dysphagia.
Study Design: Retrospective diagnostic accuracy study.
Setting: Specialty dysphagia clinic at a tertiary care center.
Supportive Care Needs From Mid-to Long-Term Follow-Up Among Head and Neck Cancer Survivors: A Longitudinal Cohort Study.
Psychooncology
September 2025
Cancer Center Amsterdam Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Background: There is limited knowledge on the supportive care needs (SCNs) of head and neck cancer (HNC) survivors during long-term survivorship.
Aims: To investigate SCNs from 2 to 5 years after treatment among HNC survivors, and its association with demographic, personal, clinical, physical, psychological, social and lifestyle, and cancer-related quality of life factors.
Methods: SCNs were measured at 2, 3, 4 and 5 years using the supportive care needs survey (SCNS-SF34 and SCNS-HNC) in 403 HNC survivors.
Prevalence of Long-Term Dysphagia in Head and Neck Cancer Survivors Not Receiving Dysphagia Treatment.
Laryngoscope
September 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Objective: In head and neck cancer (HNC) survivors not actively receiving dysphagia care, long-term dysphagia prevalence, dysphagia-related complications, and quality of life outcomes remain poorly understood. Understanding these outcomes is critical for creating effective HNC survivorship programs.
Methods: HNC survivors who completed cancer treatment > 2 years prior who had not undergone a swallow evaluation or therapy for > 1 year completed the MD Anderson Dysphagia Inventory (MDADI) and reported dysphagia-related complications.